FDA Grants Approval for Gadobutrol ANDA219287 by Viwit Pharm
The FDA's approval of Gadobutrol by Viwit Pharm introduces a new competitor in the contrast agent market, which could disrupt existing market dynamics. Pharma strategy teams need to evaluate the implications for pricing and market share of current products in this therapeutic area.
Asset
Gadobutrol
Indication
Imaging / Contrast Agent
Status
Approved
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The FDA's approval of Gadobutrol by Viwit Pharm introduces a new competitor in the contrast agent market, which could disrupt existing market dynamics. Pharma strategy teams need to evaluate the implications for pricing and market share of current products in this therapeutic area.
Why it matters
The FDA's approval of Gadobutrol by Viwit Pharm introduces a new competitor in the contrast agent market, which could disrupt existing market dynamics. Pharma strategy teams need to evaluate the implications for pricing and market share of current products in this therapeutic area.
What changed
Regulatory Approval
Analysis
The FDA has granted approval for the ANDA219287 application for Gadobutrol submitted by Viwit Pharm.
The FDA's approval of Gadobutrol by Viwit Pharm introduces a new competitor in the contrast agent market, which could disrupt existing market dynamics. Pharma strategy teams need to evaluate the implications for pricing and market share of current products in this therapeutic area.
Monitor market entry timelines and initial sales performance of Gadobutrol by Viwit Pharm.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.